Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.45
+0.06004.32%
Post-market: 1.450.00000.00%19:38 EDT
Volume:2.65M
Turnover:3.87M
Market Cap:121.38M
PE:-0.50
High:1.53
Open:1.42
Low:1.41
Close:1.39
Loading ...

Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements

TIPRANKS
·
15 Jan

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

TipRanks
·
14 Jan

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks
·
14 Jan

Editas Medicine announces strategic priorities, 2025 key milestones

TIPRANKS
·
13 Jan

Editas Medicine Inc - Has Operational Runway Into Q2 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Inc - to Submit at Least One Ind/Cta by 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Highlights New in Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-Year Strategic Priorities

THOMSON REUTERS
·
13 Jan

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Dow Jones
·
13 Jan

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks
·
16 Dec 2024

Editas Medicine Cut to Underweight From Neutral by JP Morgan

Dow Jones
·
16 Dec 2024

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

MT Newswires Live
·
16 Dec 2024

U.S. RESEARCH ROUNDUP-Amazon, Ford, Netflix

Reuters
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)

TIPRANKS
·
16 Dec 2024

Editas Medicine Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
16 Dec 2024

Editas Medicine: Strategic Shift and Uncertainties Prompt Hold Rating

TIPRANKS
·
14 Dec 2024

Editas Medicine price target lowered to $8 from $10 at Baird

TipRanks
·
14 Dec 2024

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Investing.com
·
14 Dec 2024

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

GuruFocus.com
·
14 Dec 2024